Datapoint: Appeals Court Invalidates Gilenya Patent

Reversing a lower court decision, a U.S. federal appeals court last week found a key patent for Novartis’ Gilenya invalid, opening the floor for HEC Pharm Co.’s generic challenger. The patent covers the drug’s dosing schedule — 0.5 mg per day — in relapsing multiple sclerosis patients. Novartis says it will contest the ruling. Gilenya was Novartis’ third best-selling drug in 2021, bringing in $2.79 billion in sales. For the treatment of multiple sclerosis, virtually all insured lives (99%) have covered or better access to Gilenya under the pharmacy benefit. 11% of insured lives have preferred access to Gilenya without utilization management restrictions.

SOURCE: MMIT Analytics, as of 6/22/22, and Evaluate Pharma.

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
November 28

Datapoint: Froedtert Health Set to Acquire Wisconsin Insurer

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
November 27

Datapoint: Express Scripts to Offer New “Cost-Plus” Pricing Model

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
November 16

Datapoint: Novo Nordisk Says Most People Are Paying Less Than $25 a Month for Wegovy

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today